Let's provide access to medical cannabis AND do research at the same time (with bonus graphs)
Everything you ever wanted to know about #patient #access to #medical #cannabis in #Australia in one article. Stoked to have co-written this piece with Dr Melissa Benson from the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney! You can read the full article here on page 188 of Health Europa Quarterly issue 10.
And please enjoy these bonus graphs below updated with new data. Although I recommend you read the article first!
First off, some of you may have already seen me post this a couple of weeks ago, but here are the national figures for SAS-B approvals up to June 2019.
But wait, there's more! We also have updated condition-specific data up to the end of May 2019. Here's the same graph from the article with an additional three months of data.
And here's the breakdown of 'other' conditions updated as of May 2019.
Next up, some age range breakdowns. Nothing more satisfying than a nice bell curve.
Here we have updated figures on where these approvals are coming from by State/Territory up to May 2019.
And finally, to put this in perspective, I've calculated the number of approvals in May 2019 per 100,000 people in each State/Territory. This gives you a 'per-capita' idea of which regions are seeing the most approvals given their relative size.
Head of Philanthropy at WEHI (Walter and Eliza Hall Institute of Medical Research)
5 年Good on you Justin!
Chronic Pain Patient Advocate & Writer - Volunteer Aged Care Community Worker at Medically Retired
5 年Excellent info, thank you! This week is National Pain Week. Many thanks to Chronic Pain Australia & AJP [Australian Journal of Pharmacy] for including part of my story, & I even got to highlight how medicinal cannabis has allowed me to reduce my regular opiate dosage by 50% in the last 6mths or more. Plus this comment is encouraging: "Chronic Pain Australia would like to see medicinal cannabis treated in the same way as any other legal treatment option, subject to the same regulatory standards and evidence as all other medications used in the treatment of pain." https://ajp.com.au/news/ending-the-stigma/?fbclid=IwAR2ND7jGRCxg8cDjVrI3V9-ZR25r37qV1f7BC-1jk1S50uCGMFReSYAfyPY
How Marketing and Sales meet AI => Join my newsletter | $0 -> +$10m Rev X2 | Investor | Father of 2
5 年Great summary Rhys Cohen!
Non Executive Director - Co-Founder MedReleaf Australia - Free Thinking / Entrepreneurship / Consulting / Directorship
5 年Great data Rhys.